In 2024, Healio covered several stories about trials investigating geographic atrophy biomarkers and treatment options.

While one trial found that intravitreal pegcetacoplan showed promise in slowing the growth rate of biomarkers, another showed that oral minocycline may not reduce geographic atrophy enlargement.

Here are our most popular geographic atrophy stories from 2024.

The first patient dosed in the second part of the trial for AVD-104 to treat geographic atrophy

Aviceda Therapeutics announced the dosing of the first patient in the second part of its phase 2/3 SIGLEC trial investigating AVD-104 to treat geographic atrophy secondary to age-related macular degeneration.

“Based on the efficacy and safety we saw in part 1, we moved rapidly to initiate part 2 by activating sites and enrollment for this potentially disease-modifying treatment,” David Callanan, MD, Aviceda’s chief medical officer and senior vice president, said in a company press release. Read more.

AREDS2 supplement slows expansion of geographic atrophy, even in late-stage AMD

Taking a daily supplement with antioxidant vitamins and minerals may slow the progression of late-stage dry AMD and could help maintain central vision in affected patients, according to researchers at NIH.

The original Age-Related Eye Diseases Study (AREDS), published in 2001, found that a supplement formulated with antioxidants — including vitamins C, E, and beta-carotene — as well as zinc and copper could slow the progression of intermediate to late-stage AMD. More than a decade later, the AREDS2 trial published in 2013 determined that substituting the antioxidants lutein and zeaxanthin for beta-carotene could not only improve efficacy but also prevent some risks.

Read more: https://www.healio.com/news/optometry/20241218/a-look-at-geographic-atrophy-in-2024-the-highs-lows-of-treatment-trials?utm_source=selligent&utm_medium=email&utm_campaign=news

Source: Healio.com